Big pharmaceutical companies like Merck (NYSE:MRK) are facing a major hurdle- it takes a lot of work and money in order to get a new drug to market. From beginning research to running clinical trials, creating new therapies is a daunting task. That task becomes even more daunting as robust cash flows from blockbuster drugs begin to dry up as they go off patent.
In order to save on expenses and costs, biotech and drug manufacturers have started outsourcing various steps in the process to independent lab firms. Growth in these contract research organizations (CROs) has been staggering as more and more healthcare firms begin to use their services.
For investors, the CROs offer a unique play on the drug industry.

Discount Brokers Comparison: Your one-stop shop for finding the perfect broker for your investments.

Dwindling Internal Spending, More Outsourcing
With more than $106.9 billion worth of annual branded drugs sales coming off patent, from now until 2020, Big Pharma needs to reinvent its pipeline. However, R&D budgets are failing to keep with rising expenses. According to analysts at investment bank Jeffries, R&D spending by large pharmaceutical firms only rose by tiny 1.2% in 2011. Scary still was the 1.1% contraction last year as drug manufacturers wrestled with Obamacare changes. The bank expects drug makers to increase their spending by only 0.7% in 2013. 
Yet it still takes a lot of work to get new drugs to market.
That’s where the CROs come in. These labs are hired by drug developers and medical device makers to offer research services such as overseeing preclinical and clinical testing of healthcare products during various stages of development. Given the mandates to reduce R&D costs while decreasing the time it takes to launch new drugs, business at the CROs is booming. Jefferies expects to see a 6% rise in outsourcing spending this year to reach nearly $26 billion.
The long term picture is rosy as well.
The industry has started to adopt a strategic partnership model that will ultimately benefit both pharmaceutical firms and CROs. This has allowed major drug makers to pair up with leading CROs as long-term partners in research and development. As such, healthcare intelligence company GBI Research estimates that the CRO industry will grow at a compound annual growth rate (CAGR) of 12.8% and reach $56 billion in size by 2018. 

SEE: 5 Must-Have Metrics For Value Investors
Adding The CRO Winners
Given the potential growth in the industry, investors may want to make a play for the contract research players. With stagnant R&D budgets and rising costs, the CROs are in a sweet spot to profit as various biotech and drug makers tap them to run more and more clinical trials. While some broad-based healthcare funds- like the First Trust Health Care AlphaDEX (NYSE:FXH) –do provide exposure to some CROs such as Covance (NYSE:CVD). That exposure is muted. For investors, individual picks are best.
And one of the best could be Ireland-based ICON (Nasdaq:ICLR). The firm wears the crown at signing long term deals with some of the world's largest drug makers. Back in 2011, ICON- along with rival Parexel (Nasdaq:PRXL) -signed a five-year deal with healthcare giant Pfizer (NYSE:PFE) to conduct clinical trials. Later that year, ICON was selected by Bristol-Myers Squibb (NYSE:BMY) as its preferred provider for pharmacology studies. Those partnerships have expanded the firm’s backlog by 20% and increased earnings by an astounding 92% in 2012.
Another interesting choice could be Albany Molecular Research (Nasdaq:AMRI). The small-cap firm recently reversed a year-ago loss by posting a larger profit than analyst expectations. Perhaps more importantly, the firm’s small size could make it an attractive buy-out target now that it is profitable.
Private equity buyers have shown a certain enthusiasm for CROs of late and started to gobble them up at premiums. Private equity firm, the Carlyle Group (NYSE:CG) purchased Pharmaceutical Product Development for $3.9 billion back in 2011, while Bain Capital recently did a recapitalization of industry leader Quintiles from the private equity arm of JPMorgan Chase (NYSE:JPM). Albany could be on the radar on some other firm.

SEE: What Is Private Equity?
The Bottom Line
 The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane clinical trial and lab work. This outsourcing will be a big win for the contract research organizations like Charles River Laboratories (NYSE:CRL) and its investors.

At the time of writing, Aaron Levitt did not own any shares in any company mentioned in this article.

Related Articles
  1. Fundamental Analysis

    Ethical Investing Tutorial

    Learn everything there is to know about ethical investing.
  2. Mutual Funds & ETFs

    The Truth Behind Tactical ETF Investing

    Are tactical ETFs reasonable and effective investment strategies or just plain speculative behavior?
  3. Active Trading Fundamentals

    Five Minute Investing Tutorial

    A tutorial for people who want to manage their portfolios aggressively without having it consume their lives.
  4. Term

    What are Non-GAAP Earnings?

    Non-GAAP earnings are a company’s earnings that are not reported according to Generally Accepted Accounting Principles.
  5. Mutual Funds & ETFs

    ETF Analysis: PowerShares FTSE RAFI US 1000

    Find out about the PowerShares FTSE RAFI U.S. 1000 ETF, and explore detailed analysis of the fund that invests in undervalued stocks.
  6. Investing Basics

    A Primer On Investing In The Tech Industry

    The tech sector can provide fantastic returns for investors with a little know-how in the field.
  7. Options & Futures

    Use Options to Hedge Against Iron Ore Downslide

    Using iron ore options is a way to take advantage of a current downslide in iron ore prices, whether for producers or traders.
  8. Stock Analysis

    Fortinet: A Great Play on Cybersecurity

    Discover how a healthy product mix, large-business deal growth and the boom of the cybersecurity industry are all driving Fortinet profits.
  9. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  10. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Middle Market

    Definition of middle market
  6. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  5. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  6. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!